Researchers at the University of Illinois at Chicago have discovered a possible target to treat bloodstream bacterial infections.(original article)

Mylan Inc. (NYSE:MYL) announced today that it and Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE:FRX) have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic(TM) (nebivolol), which is currently approved in the United States for the treatment of hypertension.(original article)

Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, announced today that six million doses of Stamaril(TM)(1) yellow fever vaccine have been shipped upon UNICEF’s request to respond to the yellow fever epidemic in Latin America.(original article)

Radio frequency identification technology, or RFID, has inspired many novel applications of late, including efforts to study magazine reader patterns, access restricted areas, locate stolen vehicles and track luggage at major airports.(original article)

Scientists at NanoBio Corporation and the University of Michigan have demonstrated their nasally delivered vaccinia vaccine can protect animals against 77 times the potentially lethal dose of smallpox, and without the safety risks of current vaccines for smallpox.(original article)

Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, and CollaGenex Pharmaceuticals, Inc. has announced a definitive agreement pursuant to which Galderma’s U.S. holding company, Galderma Laboratories, Inc., will acquire all of the outstanding shares of CollaGenex at a price of $16.60 per share in cash, representing approximately $420 million for the equity of CollaGenex.(original article)

Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by GlaxoSmithKline in connection with its Avodart(R) (dutasteride) soft gelatin capsules, 0.5mg.(original article)

Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy.(original article)

PolyTherics Limited, a biopharmaceutical spin-out company from Imperial College London and the London School of Pharmacy, and Celtic Pharma Development Services Bermuda Ltd, a subsidiary of Celtic Pharmaceutical Holdings LP, a global private equity investment fund focused on the biopharma industry, today announced that they have entered into a broad research collaboration agreement.(original article)

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.(original article)

Blood clots can save lives, staunching blood loss after injury, but they can also kill. Let loose in the bloodstream, a clot can cause a heart attack, stroke or pulmonary embolism.(original article)

Up to 20 percent of patients taking aspirin to lower the risk of suffering a second cerebrovascular event do not have an antiplatelet response from aspirin, the effect thought to produce the protective effect, researchers at the University at Buffalo have shown.(original article)

According to new research from Britain, new generation anti-depressants could be for many patients a waste of time and money and offer little clinical benefit.(original article)

World governments are focussing too much on fighting terrorism while obesity and other “lifestyle diseases” are killing millions more people, an international conference heard Monday.Overcoming deadly factors such as poor diet, smoking and a lack of exercise should take top priority in the fight against a growing epidemic of chronic disease, legal and health experts […](original article)

A technique that specifically “tags” tumors responding to chemotherapy may offer a new strategy for determining a cancer treatment’s effectiveness within days of starting treatment, according to a new study by Vanderbilt-Ingram Cancer Center investigators.(original article)